OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE), today
announced that it will host an audio/web conference to discuss its
global immuno-oncology partnership agreement with BoehringerIngelheim,
after the market close, on Thursday, April 5, 2018 at 6:00 p.m. CET
(12:00 p.m. EDT).

Audio playback numbers and reference (available during 90 days from
the conference call):

France +33 (0)1 72 72 74 02UK +44 20 3364 5147US +1 (646)
722-4969

Access code: 418751388#

ABOUT OSE Immunotherapeutics

OSE Immunotherapeutics is a biotechnology company focused on the
development of innovative immunotherapies for immune activation and
regulation in the fields of immuno-oncology and autoimmune diseases.
Neoepitopes innovation (Tedopi®) is today in Phase 3 in advanced lung
cancers (NSCLC) after Checkpoint Inhibitors failure (anti PD-1 and anti
PD-L1). A global license and collaboration agreement was signed in April
2018 with Boehringer Ingelheim to develop checkpoint inhibitor OSE-172
(anti-SIRPa monoclonal antibody), for the treatment of advanced solid
tumors.

An option to license was exercised in July 2016 by Janssen Biotech to
continue clinical development of FR104 (an anti CD28 mAb) in auto-immune
diseases after positive phase 1 results. A 2-step license option was
signed in 2017 with Servier Laboratories to develop OSE-127 to develop
the product up to the completion of a phase 2 clinical trial planned in
autoimmune bowel disease and Sjogren disease. The company has several
scientific and technological platforms: neoepitopes, agonist or
antagonist monoclonal antibodies, ideally positioned to fight cancer and
autoimmune diseases. Its first-in-class clinical portfolio offers a
diversified risk profile.

This press release contains express or implied information and
statements that might be deemed forward-looking information and
statements in respect of OSE Immunotherapeutics. They do not constitute
historical facts. These information and statements include financial
projections that are based upon certain assumptions and assessments made
by OSE Immunotherapeutics’ management in light of its experience and its
perception of historical trends, current economic and industry
conditions, expected future developments and other factors they believe
to be appropriate.

These forward-looking statements include statements typically using
conditional and containing verbs such as “expect”, “anticipate”,
“believe”, “target”, “plan”, or “estimate”, their declensions and
conjugations and words of similar import.

Although the OSE Immunotherapeutics management believes that the
forward-looking statements and information are reasonable, the OSE
Immunotherapeutics’ shareholders and other investors are cautioned that
the completion of such expectations is by nature subject to various
risks, known or not, and uncertainties which are difficult to predict
and generally beyond the control of OSE Immunotherapeutics. These risks
could cause actual results and developments to differ materially from
those expressed in or implied or projected by the forward-looking
statements. These risks include those discussed or identified in the
public filings made by OSE Immunotherapeutics with the AMF. Such
forward-looking statements are not guarantees of future performance.

This press release includes only summary information and should be read
with the OSE Immunotherapeutics Reference Document filed with the AMF on
28 April 2017 under the number R.17-038, including the annual financial
report for the fiscal year 2016, available on the OSE
Immunotherapeutics’ website.

Other than as required by applicable law, OSE Immunotherapeutics issues
this press release at the date hereof and does not undertake any
obligation to update or revise the forward-looking information or
statements.